A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...

East Hanover, N.J., Aug. 7, 2024 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class ...

SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Company to Present Pipeline Updates at 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ...

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...